NORMENT, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Department of Psychiatry, Telemark Hospital, Skien, Norway.
Nord J Psychiatry. 2024 Apr;78(3):212-219. doi: 10.1080/08039488.2024.2305806. Epub 2024 Feb 2.
Psychotropic and somatic medications are both used in treating severe mental disorders (SMDs). Realistic estimates of the prevalence of use across medication categories are needed. We obtained this in a clinical cohort of patients with SMD and healthy controls (HCs).
Prescriptions filled at Norwegian pharmacies the year before and after admittance to the Thematically Organized Psychosis (TOP) study were examined in 1406 patients with SMD (mean age 32.5 years, 48.2% women) and 920 HC (34.1 years, 46.2% women). Using data from the Norwegian Prescription Database (NorPD), the number of users in different anatomical therapeutic chemical (ATC) categories was compared using logistic regression. Population estimates were used as reference data.
Use of antipsychotics (N05A), antiepileptics (N03A), antidepressants (N06A), anxiolytics (N05B), hypnotics and sedatives (N05C), anticholinergics (N04A), psychostimulants, attention deficit hyperactivity disorder and nootropic agents (N06B) and drugs for addiction disorders (N07B) was significantly more prevalent in patients with SMD than HC. Use of diabetes treatment (A10), antithrombotic drugs (B01), beta blockers (C07), lipid modifiers (C10), and thyroid and endocrine therapeutics (H03) was also more prevalent in patients with SMD, but with two exceptions somatic medication use was comparable to the general population. Among HC, there was low prevalence of use for most medication categories.
Patients were using psychiatric medications, but also several types of somatic medications, more often than HC. Still, somatic medication use was mostly not higher than in the general population. The results indicate that HC had low use of most medication types.
精神药物和躯体药物均用于治疗严重精神障碍(SMD)。需要对各种药物类别的使用流行率进行现实估计。我们在一组患有 SMD 的患者和健康对照者(HC)的临床队列中获得了这些信息。
检查了 1406 名患有 SMD(平均年龄 32.5 岁,48.2%为女性)和 920 名 HC(34.1 岁,46.2%为女性)的患者在挪威药房填写的前一年和后一年的处方。使用挪威处方数据库(NorPD)的数据,使用逻辑回归比较了不同解剖治疗化学(ATC)类别的使用者数量。使用人口估计作为参考数据。
抗精神病药(N05A)、抗癫痫药(N03A)、抗抑郁药(N06A)、镇静剂(N05B)、催眠药和镇静剂(N05C)、抗胆碱能药(N04A)、精神兴奋剂、注意力缺陷多动障碍和益智药(N06B)和药物滥用障碍(N07B)的使用在 SMD 患者中明显更为常见,而 HC 则较少。糖尿病治疗(A10)、抗血栓药物(B01)、β 受体阻滞剂(C07)、血脂调节剂(C10)和甲状腺及内分泌治疗(H03)的使用在 SMD 患者中也更为常见,但有两个例外,躯体药物的使用与一般人群相当。在 HC 中,大多数药物类别的使用流行率较低。
与 HC 相比,患者使用精神科药物,但也使用几种类型的躯体药物更为频繁。尽管如此,躯体药物的使用大多并未高于一般人群。结果表明,HC 对大多数药物类型的使用频率较低。